AKAP1 and atrial fibrillation: Secondly, while our study suggests that AKAP1 overexpression may effectively improve mitochondrial homeostasis and reduce the ibrutinib-induced AF risk, there is currently a lack of targeted AKAP1-activating drugs for clinical use.